All GLG News Analyses Filed Under: Ophthalmology

Steve RubinsteinOptometristSound Shore Vision Care

The "cure" for Macular Degeneration? Maybe!

January 22, 2008

Analysis of:Telescopic IOL device shows potential for improving quality of life in AMD patients | www.osnsupersite.com

Macular degeneration is a condition where the central part of the retina is lost. This item places an image on the retina that is so big, it allows the use of the remaining, useful retina. Sounds great! It may be, however, as with many low vision devices, there are some potential pitfalls.

Promising News for AMD

January 21, 2008

Analysis by: GLG Expert Contributor

Analysis of:Telescopic IOL device shows potential for improving quality of life in AMD patients | www.osnsupersite.com

"Customized" intraocular lenses are gradually making their way into the mainstream of ocular surgery. First there were multifocal and accommodating IOLs. Now there are toric IOLs. And the future is upon us for more sophisticated designs such as the telescopic IOL.  As with any new technology, especially one that addresses such a specialized subset of patients, it will be some time before there is a consensus of opinion based upon a broad patient base.

A Holy Grail For Aging Eyes

December 7, 2007

Analysis by: GLG Expert Contributor

Analysis of:Visioneering sees solid investor interest following SEBIO event | www.techjournalsouth.com

The potential market for a newer and better optical solution to the problem of presbyopia is limitless.  Any optical system which functions with fewer "compromises" than those we have now will be a welcome addition even if its application is limited to just contact lenses alone. Broader applications to intraocular lenses and refractive surgery would be "icing" on the cake.

Robert DevenyiProfessor and Chief of OphthalmologyUNIVERSITY OF TORONTO

Genentech enrages vitreoretinal specialists

December 6, 2007

Analysis of:Genentech to cease supplying bevacizumab to compounding pharmacies | www.osnsupersite.com

-Retinal community unites against Genentech -both the American Association of Ophthalmology and the American Society of Retinal Specialists have condemned Genentech's actions -this represents profit-driven pharma at their worst -very poor decision by Genentech...not only to galvanize the profession they should be seeking to court against them...but also to put at risk hundreds of thousands of patients -myriad very interesting legal points are raised

Steve RubinsteinOptometristSound Shore Vision Care

Is this the next design for your presbyopic correction of contact lens, laser vision, or cataract procedure?

November 30, 2007

Analysis of:Visioneering sees solid investor interest following SEBIO event | www.techjournalsouth.com

The article points out that a small percentage of contact lenses and laser vision correction procedures, and cataract procedures deal with presbyopia. The field is wide open for improvement and exploitation. Numerous companies are looking for the "next best" idea.

COMBIGAN (AGN) will not add much to the Lucrative Glaucoma Market.

November 9, 2007

Analysis by: GLG Expert Contributor

Analysis of:Allergan, Inc. Receives FDA Approval For COMBIGAN™ (Brimonidine Tartrate/timolol Maleate Ophthalmic Solution) 0.2%/0.5% | www.medicalnewstoday.com

Combigan is a glaucoma medication which combines a beta blocker and alpha agonist. Although combination drugs are great for glaucoma management, this will NOT be a first line medication in treating glaucoma.  The prostaglandins (PFE, ACL) are still the gold standard IOP lowering agents in the management of glaucoma.

Andrew DahlPresident Ophthalmology Consultants

U.S. Ophthalmologists Still Waiting for Prostaglandin/Timolol Combo

November 8, 2007

Analysis of:Allergan, Inc. Receives FDA Approval For COMBIGAN™ (Brimonidine Tartrate/timolol Maleate Ophthalmic Solution) 0.2%/0.5% | www.medicalnewstoday.com

The market for eye drops for the treatment of open angle glaucoma is huge. Profit potential for pharmaceutical companies, however, is limited by the time period that they are afforded patent protection. Combigan, the just approved brimonidine/timolol combination therapy, affords Allergan new patent rights on the combination whose two components individually have multiple generic competitors.                          

New Glaucoma Product Should Simplify Patient Compliance and Increase Allergan's Share of Glaucoma Market

November 6, 2007

Analysis by: GLG Expert Contributor

Analysis of:Allergan, Inc. Receives FDA Approval For COMBIGAN™ (Brimonidine Tartrate/timolol Maleate Ophthalmic Solution) 0.2%/0.5% | www.medicalnewstoday.com

Patient compliance with glaucoma eyedrops is a key barrier in achieveing acceptable clinical outcomes. There is only one other product, Cosopt (by Merck) that offers a combination glaucoma medication. This medication may become a popular choice for glaucoma doctors to improve patient compliance.

Darcy RyanOptometristHertzog Eye Associates

Bausch & Lomb Currently Faces 573 Product Liability Lawsuits Stemming From Eye Infections Caused by ReNu MoisturLoc Contact Lens Solution

November 2, 2007

Analysis of:Bausch & Lomb Continues To Be Served With Lawsuits As A Result of Eye Infections Caused by Renu MoisturLoc Contact Lense Solution, Some Of Which Was Manufactured In Greenville, SC Plant | charleston.injuryboard.com

Even though Bausch & Lomb appears to be getting back on its feet in the contact lens and solution market, their lawsuit woes continue to pile up.  At 573 and counting, these lawsuits are expected to cost them over $1 billion.

GENETECH BACKTRACKS ON ITS DECISION TO LIMIT AVASTIN FOR WET MACULAR DEGERNATION

October 31, 2007

Analysis by: GLG Expert Contributor

Analysis of:Genentech revisits plan for Avastin | www.sfgate.com

In the two weeks since Genetech made its announcement that it would limit the availability of Avastin to ophthalmologists for use in treating wet macular degeneration the outcry from patients, ophthalmologists, politicians, and the American Academy of OPhthalmology has been so great that Genetech is reversing its position. In the two weeks since Genetech made its announcement that it would limit the availability of Avastin to ophthalmologists for use in treating wet macular degeneration the outcry from patients, ophthalmologists, politicians, and the American Academy of OPhthalmology has been so great that Genetech is reversing its position.

Previous Page : 45678910111213Next81 to 90 of 304